| Description |
-
Background: Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study. The objective of this ... read morephase II study was to expand upon the initial findings and assess the activity and safety in a larger population of dogs with lymphoma.
Keywords: Non-Hodgkin lymphoma, Nuclear export, Clinical trial, Anti-tumor agent.
Springer Open.read less
|
|---|
This object is in collection
